Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy BHVN Stock  Free BHVN Stock Alerts

Biohaven (BHVN) Financials

Biohaven logo
$16.22 +0.47 (+2.98%)
As of 05/20/2025 03:58 PM Eastern
Compare
Annual Income Statements for Biohaven

Annual Income Statements for Biohaven

This table shows Biohaven's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders		 -846 -408 -570 -214 -119
Consolidated Net Income / (Loss)		 -846 -408 -570 -214 -119
Net Income / (Loss) Continuing Operations		 -846 -408 -570 -214 -119
Total Pre-Tax Income 		-846 -410 -570 -212 -119
Total Operating Income		 -885 -436 -568 -219 -115
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 885 436 568 219 115
Selling, General & Admin Expense		 89 63 131 37 16
Research & Development Expense		 796 373 437 181 98
Total Other Income / (Expense), net		 39 27 -1.91 6.47 -4.16
Other Income / (Expense), net		 39 27 -1.91 1.21 0.00
Income Tax Expense		 0.74 -1.38 0.44 1.37 0.00
Basic Earnings per Share		 ($9.28) ($5.73) ($12.75) ($5.43) ($3.01)
Weighted Average Basic Shares Outstanding		 91.23M 71.20M 44.74M 39.38M 39.38M
Diluted Earnings per Share		 ($9.28) ($5.73) ($12.75) ($5.43) ($3.01)
Weighted Average Diluted Shares Outstanding		 91.23M 71.20M 44.74M 39.38M 39.38M
Weighted Average Basic & Diluted Shares Outstanding		 102.05M 81.58M 68.21M - -

Quarterly Income Statements for Biohaven

This table shows Biohaven's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -187 -160 -320 -180 -145 -102 -90 -70 -201 -69
Consolidated Net Income / (Loss)		 -187 -160 -320 -180 -145 -103 -90 -70 -201 -69
Net Income / (Loss) Continuing Operations		 -187 -160 -320 -180 -145 -103 -90 -70 -201 -69
Total Pre-Tax Income 		-187 -160 -320 -179 -146 -106 -88 -70 -215 -68
Total Operating Income		 -190 -178 -334 -183 -154 -111 -94 -78 -213 -68
Total Operating Expenses		 190 178 334 183 154 111 94 78 213 68
Selling, General & Admin Expense		 22 21 19 27 19 15 15 14 76 15
Research & Development Expense		 167 158 315 156 135 96 79 63 137 53
Total Other Income / (Expense), net		 3.14 18 14 4.31 7.74 4.69 5.84 8.23 -1.84 0.00
Income Tax Expense		 0.05 -0.06 0.18 0.57 -1.21 -3.29 2.18 0.94 -14 1.22
Basic Earnings per Share		 ($1.74) ($1.70) ($3.64) ($2.20) ($1.88) ($1.50) ($1.32) ($1.03) ($3.38) ($1.75)
Weighted Average Basic Shares Outstanding		 91.23M 94.37M 87.77M 81.60M 71.20M 68.32M 68.25M 68.21M 44.74M 39.38M
Diluted Earnings per Share		 ($1.74) ($1.70) ($3.64) ($2.20) ($1.88) ($1.50) ($1.32) ($1.03) ($3.38) ($1.75)
Weighted Average Diluted Shares Outstanding		 91.23M 94.37M 87.77M 81.60M 71.20M 68.32M 68.25M 68.21M 44.74M 39.38M
Weighted Average Basic & Diluted Shares Outstanding		 102.05M 101.12M 94.54M 88.29M 81.58M 80.23M 68.32M 68.22M 68.21M -

Annual Cash Flow Statements for Biohaven

This table details how cash moves in and out of Biohaven's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents		 -150 9.52 166 -6.45 74
Net Cash From Operating Activities		 -582 -332 -298 -146 -76
Net Cash From Continuing Operating Activities		 -582 -332 -298 -146 -76
Net Income / (Loss) Continuing Operations		 -846 -408 -570 -214 -119
Consolidated Net Income / (Loss)		 -846 -408 -570 -214 -119
Depreciation Expense		 7.86 6.91 1.39 1.39 0.07
Non-Cash Adjustments To Reconcile Net Income		 239 45 300 65 34
Changes in Operating Assets and Liabilities, net		 17 25 -29 1.66 8.98
Net Cash From Investing Activities		 -245 130 -305 0.94 -2.70
Net Cash From Continuing Investing Activities		 -245 130 -305 0.94 -2.70
Purchase of Property, Plant & Equipment		 -4.05 -3.05 -6.07 -0.94 -1.10
Acquisitions		 0.39 0.00 -35 1.88 0.00
Purchase of Investments		 -746 -194 -260 0.00 0.00
Sale and/or Maturity of Investments		 504 327 0.00 0.00 -
Other Investing Activities, net		 0.00 0.00 -4.00 0.00 -1.60
Net Cash From Financing Activities		 678 212 768 138 152
Net Cash From Continuing Financing Activities		 678 212 768 138 152
Repayment of Debt		 2.26 0.00 0.00 - 0.00
Repurchase of Common Equity		 -2.15 -0.80 -1.00 0.00 0.00
Issuance of Common Equity		 678 248 733 138 92
Other Financing Activities, net		 0.00 -35 35 0.00 60
Effect of Exchange Rate Changes		 0.08 -0.50 0.43 0.00 0.00
Cash Interest Paid		 0.13 0.00 0.00 0.11 0.00
Cash Income Taxes Paid		 -10 -33 38 17 2.76

Quarterly Cash Flow Statements for Biohaven

This table details how cash moves in and out of Biohaven's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 15 -154 55 -65 126 -76 11 -52 191 27
Net Cash From Operating Activities		 -171 -141 -168 -103 -115 -95 -44 -78 -75 -96
Net Cash From Continuing Operating Activities		 -171 -141 -168 -103 -115 -95 -44 -78 -75 -96
Net Income / (Loss) Continuing Operations		 -187 -160 -320 -180 -145 -103 -90 -70 -201 -69
Consolidated Net Income / (Loss)		 -187 -160 -320 -180 -145 -103 -90 -70 -201 -69
Depreciation Expense		 2.46 1.99 1.95 1.45 1.89 1.54 1.83 1.65 0.34 0.38
Non-Cash Adjustments To Reconcile Net Income		 20 -3.48 173 50 37 3.44 2.76 2.02 126 17
Changes in Operating Assets and Liabilities, net		 -6.02 21 -23 26 -8.72 2.78 41 -11 -1.00 -44
Net Cash From Investing Activities		 -88 -93 -98 34 -3.91 59 76 -1.06 -264 -4.52
Net Cash From Continuing Investing Activities		 -88 -93 -98 34 -3.91 59 76 -1.06 -264 -4.52
Purchase of Property, Plant & Equipment		 -0.05 -0.61 -2.95 -0.44 -0.47 -1.25 -0.60 -0.74 -0.30 -4.52
Purchase of Investments		 -280 -223 -196 -47 -111 -29 -24 -30 -260 -
Sale and/or Maturity of Investments		 192 130 101 81 108 89 100 29 - -
Net Cash From Financing Activities		 273 80 321 3.42 245 -40 -20 27 530 128
Net Cash From Continuing Financing Activities		 273 80 321 3.42 245 -40 -20 27 530 128
Repurchase of Common Equity		 -1.35 - - - -0.80 - - - - -
Issuance of Common Equity		 283 76 - - 248 - - - 496 128
Other Financing Activities, net		 -8.58 4.01 2.37 2.20 -0.03 -42 -20 27 35 -
Effect of Exchange Rate Changes		 0.09 - -0.01 -0.01 -0.31 -0.04 -0.16 0.02 0.43 -

Annual Balance Sheets for Biohaven

This table presents Biohaven's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Total Assets		 615 513 662 142
Total Current Assets		 538 442 587 95
Cash & Equivalents		 99 248 205 76
Short-Term Investments		 387 133 260 0.00
Prepaid Expenses		 49 35 21 6.73
Current Deferred & Refundable Income Taxes		 2.60 13 46 9.91
Other Current Assets		 0.51 12 19 2.12
Plant, Property, & Equipment, net		 17 17 18 13
Total Noncurrent Assets		 59 54 57 34
Goodwill		 1.39 1.39 1.39 1.39
Intangible Assets		 18 18 18 18
Other Noncurrent Operating Assets		 40 34 38 14
Total Liabilities & Shareholders' Equity		 615 513 662 142
Total Liabilities		 192 85 123 47
Total Current Liabilities		 154 55 90 42
Accounts Payable		 18 16 11 4.78
Accrued Expenses		 51 40 44 37
Other Current Liabilities		 85 0.00 35 0.00
Total Noncurrent Liabilities		 37 30 33 5.44
Other Noncurrent Operating Liabilities		 37 30 33 5.44
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 423 428 539 35
Total Preferred & Common Equity		 423 428 539 35
Preferred Stock		 0.00 0.00 0.00 0.00
Total Common Equity		 423 428 539 35
Common Stock		 1,769 927 630 0.00
Retained Earnings		 -1,346 -499 -91 0.00
Accumulated Other Comprehensive Income / (Loss)		 0.08 -0.07 0.28 0.00

Quarterly Balance Sheets for Biohaven

This table presents Biohaven's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023
Total Assets		 511 583 419 383 507 619
Total Current Assets		 441 511 349 311 434 544
Cash & Equivalents		 84 239 183 112 148 125
Short-Term Investments		 294 198 101 129 188 263
Prepaid Expenses		 55 60 46 34 28 26
Current Deferred & Refundable Income Taxes		 5.32 7.52 8.43 13 8.66 44
Other Current Assets		 1.20 7.27 11 23 22 25
Plant, Property, & Equipment, net		 18 19 17 18 17 17
Total Noncurrent Assets		 52 53 53 54 55 57
Goodwill		 1.39 1.39 1.39 1.39 1.39 1.39
Intangible Assets		 18 18 18 18 18 18
Other Noncurrent Operating Assets		 32 33 33 35 36 37
Total Liabilities & Shareholders' Equity		 511 583 419 383 507 619
Total Liabilities		 195 199 117 93 119 146
Total Current Liabilities		 152 156 87 62 88 114
Accounts Payable		 20 17 36 9.52 12 14
Accrued Expenses		 64 58 50 53 35 38
Other Current Liabilities		 69 81 - 0.03 40 62
Total Noncurrent Liabilities		 42 43 30 31 32 32
Other Noncurrent Operating Liabilities		 42 43 30 31 32 32
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 316 384 301 290 387 472
Total Preferred & Common Equity		 316 384 301 290 387 472
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 316 384 301 290 387 472
Common Stock		 1,475 1,382 980 644 639 634
Retained Earnings		 -1,159 -999 -679 -355 -252 -162
Accumulated Other Comprehensive Income / (Loss)		 0.14 -0.08 -0.11 0.16 0.02 0.17

Annual Metrics And Ratios for Biohaven

This table displays calculated financial ratios and metrics derived from Biohaven's official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -108.09% 29.17% -162.81% -89.02% 0.00%
EBIT Growth		 -106.49% 28.13% -161.77% -90.11% 0.00%
NOPAT Growth		 -102.98% 23.22% -159.45% -91.17% 0.00%
Net Income Growth		 -107.37% 28.43% -166.74% -80.16% 0.00%
EPS Growth		 -61.95% 55.06% -134.81% -80.40% 0.00%
Operating Cash Flow Growth		 -75.58% -11.43% -104.12% -92.00% 0.00%
Free Cash Flow Firm Growth		 -63.13% 24.92% -142.71% 0.00% 0.00%
Invested Capital Growth		 -235.53% 20.77% 105.10% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.45% 14.96% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.38% 14.47% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -4.27% 12.04% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -5.23% 12.13% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 1.49% 20.75% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -10.61% -13.51% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 -5.98% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.41% -6.53% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.09% 99.66% 100.08% 100.64% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 97.58% 103.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -198.83% -84.44% -180.05% -225.78% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% -742.35% -1,467.45% -1,844.63% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -198.83% -84.44% -163.00% -82.72% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -199.89% -95.37% -105.85% -616.29% 0.00%
Net Operating Profit after Tax (NOPAT)		 -620 -305 -398 -153 -80
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -52.28% -23.33% -59.91% -159.26% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -146.32% -71.32% -73.79% - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -846 -410 -570 -218 -115
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -838 -403 -568 -216 -114
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 6.01 6.82 1.76 161.51 0.00
Price to Tangible Book Value (P/TBV)		 6.31 7.15 1.82 376.01 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 54.93 11.66 299.82 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -0.91 -0.91 -0.80 0.00
Leverage Ratio		 1.33 1.22 1.27 1.50 0.00
Compound Leverage Factor		 1.33 1.22 1.27 1.46 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 63.36% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 36.64% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.12 17.44 2.48 66.36 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 9.47% 63.36% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 3.49 7.98 6.52 2.26 0.00
Quick Ratio		 3.15 6.89 5.17 1.81 0.00
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 -511 -313 -417 -172 0.00
Operating Cash Flow to CapEx		 -14,385.11% -10,883.37% -4,901.04% -15,547.97% -6,924.07%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -63 46 38 19 0.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -109 7.94 20 19 0.00
Enterprise Value (EV)		 2,060 2,535 446 5,587 0.00
Market Capitalization		 2,546 2,917 946 5,603 0.00
Book Value per Share		 $4.19 $5.33 $12.04 $0.88 $0.00
Tangible Book Value per Share		 $3.99 $5.09 $11.60 $0.38 $0.00
Total Capital		 423 428 539 95 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -486 -382 -501 -76 0.00
Capital Expenditures (CapEx)		 4.05 3.05 6.07 0.94 1.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -102 5.20 -3.61 -23 0.00
Debt-free Net Working Capital (DFNWC)		 384 387 497 53 0.00
Net Working Capital (NWC)		 384 387 497 53 0.00
Net Nonoperating Expense (NNE)		 227 103 173 61 39
Net Nonoperating Obligations (NNO)		 -486 -382 -501 -76 0.00
Total Depreciation and Amortization (D&A)		 7.86 6.91 1.39 1.39 0.07
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 ($9.28) ($5.73) ($12.75) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 91.23M 71.20M 44.74M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($9.28) ($5.73) ($12.75) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 91.23M 71.20M 44.74M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 102.05M 81.58M 68.21M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -620 -305 -398 -153 -80
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.25% -0.20% -0.18% 0.00% 0.00%

Quarterly Metrics And Ratios for Biohaven

This table displays calculated financial ratios and metrics derived from Biohaven's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -30.12% -51.81% -284.32% -161.38% 32.96% -55.10% 56.12% 24.15% 0.00% 0.00%
EBIT Growth		 -30.12% -51.48% -278.56% -157.26% 32.19% -56.51% 55.28% 22.53% 0.00% 0.00%
NOPAT Growth		 -23.56% -61.17% -255.04% -135.58% 27.97% -63.44% 52.31% 13.36% 0.00% 0.00%
Net Income Growth		 -29.07% -56.28% -253.94% -154.64% 28.02% -48.98% 55.56% 27.35% 0.00% 0.00%
EPS Growth		 7.45% -13.33% -175.76% -113.59% 44.38% 14.29% 74.42% 58.13% 0.00% 0.00%
Operating Cash Flow Growth		 -48.63% -49.00% -277.98% -32.20% -52.35% 0.78% 34.61% -31.96% 0.00% 0.00%
Free Cash Flow Firm Growth		 79.02% 90.12% -117.60% -60.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 -235.53% -227.19% -553.80% -20.51% 20.77% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -18.38% 52.27% -86.95% -23.19% -38.10% -20.83% -27.15% 68.40% -219.52% 65.82%
EBIT Q/Q Growth		 -18.44% 51.95% -86.53% -22.59% -37.89% -20.07% -26.77% 67.69% -218.24% 65.70%
NOPAT Q/Q Growth		 -6.60% 46.62% -82.15% -19.21% -39.05% -17.59% -20.86% 63.55% -215.53% 65.69%
Net Income Q/Q Growth		 -16.56% 49.87% -78.14% -24.00% -41.12% -13.53% -28.16% 64.95% -192.08% 66.13%
EPS Q/Q Growth		 -2.35% 53.30% -65.45% -17.02% -25.33% -13.64% -28.16% 69.53% -93.14% 66.09%
Operating Cash Flow Q/Q Growth		 -20.86% 15.81% -63.49% 10.66% -21.17% -113.58% 42.82% -2.96% 21.09% -40.77%
Free Cash Flow Firm Q/Q Growth		 -93.53% 92.58% -36.48% -6.99% 8.86% -63.50% -0.52% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.41% -18.05% -395.12% -60.94% -6.53% 321.17% -48.30% -40.65% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.03% 99.96% 100.06% 100.32% 99.17% 96.90% 102.47% 101.35% 93.43% 101.80%
Interest Burden Percent		 98.35% 100.00% 95.75% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -198.83% -265.45% -193.67% -133.69% -84.44% -160.18% -111.24% -115.14% -180.05% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -1,839.37% -742.35% 0.00% 0.00% 0.00% -1,091.47% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -198.83% -265.45% -193.67% -133.69% -84.44% -160.18% -111.24% -115.14% -163.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -254.53% -194.56% -171.57% 0.00% -160.18% -111.24% -115.14% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -133 -125 -234 -128 -108 -77 -66 -54 -149 -47
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.42% -11.49% -21.20% -13.98% -8.42% -20.94% -13.07% -7.14% -10.33% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -31.40% - - - -25.14% - - - -27.73% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -190 -160 -334 -179 -146 -106 -88 -70 -215 -68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -187 -158 -332 -177 -144 -104 -86 -68 -215 -67
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 6.01 10.78 6.17 12.37 6.82 6.11 4.21 1.97 1.76 0.00
Price to Tangible Book Value (P/TBV)		 6.31 11.50 6.50 13.24 7.15 6.56 4.44 2.06 1.82 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 191.04 54.93 31.03 107.03 21.23 11.66 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.05 -0.95 -0.91 -0.83 -0.97 -0.95 -0.93 0.00
Leverage Ratio		 1.33 1.47 1.41 1.34 1.22 1.32 1.31 1.31 1.27 0.00
Compound Leverage Factor		 1.30 1.47 1.35 1.34 1.22 1.32 1.31 1.31 1.27 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.64 6.97 3.58 16.17 19.14 10.04 7.74 3.92 4.25 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.47% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.49 2.89 3.27 4.03 7.98 4.99 4.94 4.78 6.52 0.00
Quick Ratio		 3.15 2.49 2.80 3.27 6.89 3.87 3.81 3.40 5.17 0.00
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -13 -169 -124 -116 -127 -78 -77 0.00 0.00
Operating Cash Flow to CapEx		 -348,453.06% -23,122.09% -5,690.00% -23,326.59% -24,442.77% -7,597.20% -7,461.01% -10,562.99% -25,135.67% -2,112.29%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -63 -63 -53 18 46 49 12 23 38 0.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -109 -112 -65 -4.65 7.94 49 12 23 0.00 0.00
Enterprise Value (EV)		 2,060 3,027 1,929 3,444 2,535 1,532 1,255 482 446 0.00
Market Capitalization		 2,546 3,406 2,366 3,728 2,917 1,773 1,630 931 946 248
Book Value per Share		 $4.19 $3.34 $4.35 $3.70 $5.33 $4.25 $5.68 $6.92 $12.04 $0.00
Tangible Book Value per Share		 $3.99 $3.13 $4.12 $3.45 $5.09 $3.96 $5.39 $6.63 $11.60 $0.00
Total Capital		 423 316 384 301 428 290 387 472 539 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -486 -379 -437 -283 -382 -241 -376 -450 -501 0.00
Capital Expenditures (CapEx)		 0.05 0.61 2.95 0.44 0.47 1.25 0.60 0.74 0.30 4.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -102 -91 -82 -21 5.20 7.77 -29 -19 -3.61 0.00
Debt-free Net Working Capital (DFNWC)		 384 288 355 262 387 248 346 430 497 0.00
Net Working Capital (NWC)		 384 288 355 262 387 248 346 430 497 0.00
Net Nonoperating Expense (NNE)		 54 36 86 51 37 25 25 16 52 22
Net Nonoperating Obligations (NNO)		 -486 -379 -437 -283 -382 -241 -376 -450 -501 0.00
Total Depreciation and Amortization (D&A)		 2.46 1.99 1.95 1.45 1.89 1.54 1.83 1.65 0.34 0.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.74) ($1.70) ($3.64) ($2.20) ($1.88) ($1.50) ($1.32) ($1.03) ($3.38) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 91.23M 94.37M 87.77M 81.60M 71.20M 68.32M 68.25M 68.21M 44.74M 0.00
Adjusted Diluted Earnings per Share		 ($1.74) ($1.70) ($3.64) ($2.20) ($1.88) ($1.50) ($1.32) ($1.03) ($3.38) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 91.23M 94.37M 87.77M 81.60M 71.20M 68.32M 68.25M 68.21M 44.74M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 102.05M 101.12M 94.54M 88.29M 81.58M 80.23M 68.32M 68.22M 68.21M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -133 -125 -234 -128 -108 -77 -66 -54 -149 -47
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.25% -0.20% -0.21% 0.00% -0.20% 0.00% 0.00% 0.00% -0.18% 0.00%

Frequently Asked Questions About Biohaven's Financials

When does Biohaven's financial year end?

According to the most recent income statement we have on file, Biohaven's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Biohaven's net income changed over the last 4 years?

Biohaven's net income appears to be on an upward trend, with a most recent value of -$846.42 million in 2024, rising from -$118.67 million in 2020. The previous period was -$408.17 million in 2023. See Biohaven's forecast for analyst expectations on what’s next for the company.

What is Biohaven's operating income?
Biohaven's total operating income in 2024 was -$885.11 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $885.11 million
How has Biohaven revenue changed over the last 4 years?

Over the last 4 years, Biohaven's total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Biohaven have?

Biohaven's total liabilities were at $191.67 million at the end of 2024, a 124.9% increase from 2023, and a 304.6% increase since 2021.

How much cash does Biohaven have?

In the past 3 years, Biohaven's cash and equivalents has ranged from $76.06 million in 2021 to $248.40 million in 2023, and is currently $99.13 million as of their latest financial filing in 2024.

How has Biohaven's book value per share changed over the last 4 years?

Over the last 4 years, Biohaven's book value per share changed from 0.00 in 2020 to 4.19 in 2024, a change of 418.7%.


Related Companies

This page (NYSE:BHVN) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored